More than 30 from MIT named to Forbes 30 Under 30 lists
Forbes calls its 2019 30 Under 30 honorees “a collection of bold risk-takers who are putting a new twist on the old tools of the trade.”
The long and short of CDK12
A new study linking RNA processing to DNA repair may open new avenues to cancer therapy.
Measuring cancer cell “fitness” reveals drug susceptibility
Together, cell growth rate and gene expression shed light on why some tumor cells survive treatment.
With these nanoparticles, a simple urine test could diagnose bacterial pneumonia
Results could also indicate whether antibiotics have successfully treated the infection.
Potential arthritis treatment prevents cartilage breakdown
Injectable material made of nanoscale particles can deliver arthritis drugs throughout cartilage.
Squeezing cells to cure diseases
Startup SQZ Biotech aims to open a new path in immunotherapy with its cell-compressing technique.
Probiotics and antibiotics create a killer combination
Delivered together, the two join forces to eradicate drug-resistant bacteria.
Angelika Amon wins 2019 Breakthrough Prize in Life Sciences
Four other MIT researchers to receive New Horizons Prizes in math and physics; two alumni win Breakthrough Prize in Fundamental Physics.
Automated system identifies dense tissue, a risk factor for breast cancer, in mammograms
Deep-learning model has been used successfully on patients, may lead to more consistent screening procedures.
Computer model offers more control over protein design
New approach generates a wider variety of protein sequences optimized to bind to drug targets.
In pursuit of the elusive stem cell
New MIT initiative delves into the biology of stem cells and cancer stem cells, seeks ways to identify, purify, and propagate them.
Progress against pancreatic cancer
Lustgarten Foundation names MIT laboratory to improve understanding and treatment of a deadly disease
Immune cell variations contribute to malaria severity
Natural killer cells’ failure to respond to infection may explain why the disease is more grave in some patients.
A new way to manufacture small batches of biopharmaceuticals on demand
System can be rapidly reconfigured to produce a variety of protein drugs.
New perspectives at the bench
Three MIT postdocs earn competitive Howard Hughes Medical Institute fellowships that support diversity in the sciences.